作者: Joag, Vineet ; Mickelson, Clayton K ; Bold, Tyler D ; Langlois, Ryan A ; Stolley, J Michael ; Walter, Jennifer A ; Quarnstrom, Clare F ; Thiede, Joshua M ; Jenkins, Marc K ; Becker, Samuel ; Wijeyesinghe, Sathi ; Vezys, Vaiva ; Masopust, David ; Weyu, Eyob ; Vu, Michelle N ; Matchett, William E ; Shepherd, Frances K ; O’Flanagan, Stephen D ; Menachery, Vineet D ; Soerens, Andrew G

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.

2009-11-01·Biotechnology Letters4区 · 工程技术

Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice

4区 · 工程技术

Article

作者: Ling Tao ; Hui Hu ; Yabin Wang ; Liying Chen ; Hanzhong Wang ; Jihong Yang

The immunogenicity of SARS-CoV nucleocapsid DNA vaccine and the immunoregulatory activity of interleukin-2 (IL-2) were investigated. DNA vaccine plasmids, pcDNA-N and pcDNA-IL2, were constructed and inoculated into BALB/c mice with or without pcDNA-IL2 by intramuscular injection. Cellular and humoral immune responses were assessed by indirect ELISA, lymphocyte proliferation assays, ELISPOT and FACS. The nucleocapsid DNA vaccine had good immunogenicity and can induce specific humoral and cellular immunity in BALB/c mice, while IL-2 plays an immunoadjuvant role and enhances specific immune responses. This study provides a frame of reference for the design of DNA vaccines against SARS-CoV.

2005-12-01·Genetic Vaccines and Therapy

A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses

Article

作者: Susan Aucoin ; Francisco Diaz-Mitoma ; Ali Azizi ; Helina Tadesse ; Turaya Naas ; Catalina Soare ; Masoud Ghorbani ; Rita Frost

AbstractSeveral studies have shown that cell-mediated immune responses play a crucial role in controlling viral replication. As such, a candidate SARS vaccine should elicit broad CD8+ T-cell immune responses. Several groups of mice were immunized alone or in combination with SARS-nucleocapsid immunogen. A high level of specific SARS-CD8+ T-cell response was demonstrated in mice that received DNA encoding the SARS-nucleocapsid, protein and XIAP as an adjuvant. We also observed that co-administration of a plasmid expressing nucleocapsid, recombinant protein and montanide/CpG induces high antibody titers in immunized mice. Moreover, this vaccine approach merits further investigation as a potential candidate vaccine against SARS.

100 项与 Nucleocapsid vaccine (EpicentRx) 相关的药物交易

登录后查看更多信息